Zydus Lifesciences completes Assertio acquisition through tender offer

Zydus Lifesciences Limited has completed the acquisition of Assertio Holdings Inc through a cash tender offer executed by its wholly owned subsidiary, Zara Merger Sub Inc, for all outstanding Assertio common shares. The completion adds another transaction to Zydus Lifesciences Limited's recent expansion and partnership activity across international pharmaceutical markets.

How did Zydus Lifesciences complete the Assertio acquisition?

Zydus Lifesciences Limited said in a regulatory filing that it successfully completed the cash tender offer for all outstanding shares of common stock in Assertio Holdings Inc. The offer was made through Zara Merger Sub Inc, a wholly owned subsidiary of Zydus Lifesciences Limited.

The disclosed update confirms completion of the tender offer process. The available information does not state the transaction value, the number of Assertio shares acquired, a completion date, or the financial terms of the acquisition. Those details therefore cannot be assessed from the announcement.

The use of a wholly owned merger subsidiary is part of the transaction structure described in the filing. Assertio is the target company named in the completed acquisition, while Zydus is the acquiring company disclosed in the update.

What other acquisition activity has Zydus disclosed?

Zydus has also completed the acquisition of the active pharmaceutical ingredient, or API, business of Sterling Biotech Limited. The company said that transaction closed after conditions precedent under the Business Transfer Agreement dated September 17, 2024, were fulfilled.

Separately, Zydus had announced an agreement with Perfect Day Inc in August 2024 under which its wholly owned subsidiary would acquire Perfect Day's approximately 50% shareholding in Sterling Biotech Limited. The planned structure would make Sterling Biotech a 50:50 joint venture, with equal representation on the board.

Sterling Biotech is engaged in manufacturing and selling fermentation-based API products and gelatine, according to the disclosed material. The parties said the joint venture would establish a manufacturing facility for fermented animal-free protein for global markets. The information provided does not disclose the consideration for the API-business acquisition.

How is Zydus expanding pharmaceutical manufacturing in Sri Lanka?

Zydus and Sunshine Healthcare announced Zydus Sunshine Lifesciences Pvt Ltd as a strategic joint venture to establish a pharmaceutical manufacturing facility in Sri Lanka. Zydus will hold 50% of the paid-up equity share capital of Zydus Sunshine after subscribing to the shares under the Share Subscription and Shareholders' Agreement.

The project carries an investment commitment of more than USD 20 million and will be developed in phases. The Board of Investment zone in Horana is the planned location, and the facility will occupy nearly four acres of land. The foundation stone was laid on June 26, 2026, marking the formal start of the project.

The company said commercial operations are expected by 2028. The proposed plant is intended to manufacture pharmaceutical products for Sri Lanka's retail market, with the stated objective of strengthening local production and reducing dependence on imports.

The project will operate under Board of Investment oversight, with Sri Lanka's Ministry of Health and National Medicines Regulatory Authority identified as key stakeholders. Products will need to comply with National Medicines Regulatory Authority regulations and applicable pricing frameworks.

What changed in the Bayer Zydus Pharma joint venture?

Bayer Pharmaceuticals Private Limited acquired full ownership of Bayer Zydus Pharma Private Limited after purchasing Zydus' remaining 25% stake. Zydus confirmed that it had received the consideration for the transfer of 1,24,99,999 equity shares with a face value of Rs. 10 each.

Bayer Zydus Pharma was created as a 50:50 joint venture on January 28, 2011, for sales and marketing of pharmaceutical products in India. Bayer subsequently increased its holding to 75%, before exercising the pre-agreed joint venture terms to obtain the remaining stake.

Following the transfer, Bayer Zydus Pharma ceased to be a joint venture of Zydus. The companies described the transaction as the conclusion of their joint venture arrangement, rather than a change to the operating purpose for which it was initially formed.

Why do these transactions matter for Zydus and investors?

The completed Assertio acquisition and Sterling Biotech API-business acquisition show Zydus pursuing different routes to build its business portfolio. The Assertio transaction is a completed overseas acquisition through a tender offer, while the Sterling Biotech transaction concerns an API business with a fermentation-related manufacturing background.

The Sri Lanka project is different in nature because it is a 50:50 manufacturing joint venture with Sunshine Healthcare. Its disclosed investment commitment of over USD 20 million and expected 2028 commercial start provide the clearest available indicators of its planned scale and timeline.

For investors, the disclosures establish the legal completion of the Assertio tender offer and the exit from Bayer Zydus Pharma. However, the material provided does not include revenue contribution, earnings effect, funding details, purchase consideration for Assertio, or an integration timetable. Assessment of the financial impact would require subsequent company disclosures.

The initiatives also span several parts of the pharmaceutical value chain, including APIs, domestic pharmaceutical marketing, overseas acquisition and local manufacturing. Their operational effects will depend on execution, regulatory clearances where applicable, and the timelines disclosed by the respective entities.

Conclusion

Zydus has confirmed completion of the Assertio acquisition through a cash tender offer made by Zara Merger Sub Inc. Alongside this transaction, the company has completed the Sterling Biotech API-business acquisition, exited the Bayer Zydus Pharma joint venture, and committed to a manufacturing partnership in Sri Lanka.

The next disclosed milestone is commercial operation of the Zydus Sunshine facility, which is expected by 2028. Investors will also watch for further disclosures on the financial terms, integration and operating contribution of the Assertio acquisition, none of which were included in the material provided.